Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines

• Published in: Breast (Edinburgh) Vol. 14; no. 4; pp. 304 - 309
• Main Authors: Ahn, Jin-Hee, Kim, Sung-Bae, Sohn, Hee-Jung, Lee, Jung-Shin, Kang, Yoon-Koo, Kun Kim, Woo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.08.2005
• Subjects: Adult; Anthracycline; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast neoplasms; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cisplatin; Cisplatin - administration & dosage; Disease Progression; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia - chemically induced; Survival Analysis; Taxoids - administration & dosage; Treatment Outcome; Breast neoplasms; Anthracycline; Cisplatin; Docetaxel
• ISSN: 0960-9776; 1532-3080
• DOI: 10.1016/j.breast.2005.02.006

We evaluated the efficacy and safety of the combination of docetaxel and cisplatin in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens. Between June 1999 and December 2002, 50 female MBC patients (median age 43 years; range 29–64) received docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 on day 1 of each 4-week cycle. A total of 226 cycles (median four cycles per patient) were administered as first-line (23 patients) or second-line (27 patients) treatment. Five patients (10%) achieved a complete response (CR) and 15 (30%) had partial responses (PR), giving an overall response rate of 40% (95% CI, 26.4∼53.6%). The median duration of response was 6.1 months (range, 2.3∼29.2 + months). With a median follow-up of 15.9 months, median time to progression was 6.2 months (range 1∼22.5 + months). Toxicities included grades III and IV neutropenia in nine (18%) and ten (20%) patients, respectively, and febrile neutropenia in seven patients (14%). In conclusion, our data show that docetaxel plus cisplatin is effective with the manageable toxicity profile in MBC patients previously treated with anthracyclines.